ASAP.ST
Price:
$0.028
Market Cap:
$633.96K
Asarina Pharma AB (publ), a biotech company, researches and develops pharmaceutical products. Its flagship product is Sepranolone, which is used for the treatment of menstrual migraine and Tourette syndrome. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.
Industry
Biotechnology
IPO Date
2018-09-24
Stock Exchange
STO
Ticker
ASAP.ST
According to Asarina Pharma AB (publ)’s latest financial reports and current stock price. The company's current PE Ratio is -0.05. This represents a change of -98.13% compared to the average of -2.62 of the last 4 quarters.
The mean historical PE Ratio of Asarina Pharma AB (publ) over the last ten years is -4.22. The current -0.05 PE Ratio has changed 16.52% with respect to the historical average. Over the past ten years (40 quarters), ASAP.ST's PE Ratio was at its highest in in the June 2023 quarter at -1.03. The PE Ratio was at its lowest in in the December 2017 quarter at -21.31.
Average
-4.22
Median
-1.55
Minimum
-9.37
Maximum
-1.15
Discovering the peaks and valleys of Asarina Pharma AB (publ) PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 18.20%
Maximum Annual PE Ratio = -1.15
Minimum Annual Increase = -73.67%
Minimum Annual PE Ratio = -9.37
| Year | PE Ratio | Change |
|---|---|---|
| 2023 | -1.55 | 18.20% |
| 2022 | -1.31 | 14.51% |
| 2021 | -1.15 | -23.56% |
| 2020 | -1.50 | -73.67% |
| 2019 | -5.70 | -36.12% |
| 2018 | -8.92 | -4.75% |
The current PE Ratio of Asarina Pharma AB (publ) (ASAP.ST) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.34
5-year avg
-2.24
10-year avg
-4.22
Asarina Pharma AB (publ)’s PE Ratio is less than Cantargia AB (publ) (6.79), less than BioArctic AB (publ) (28.18), greater than Ascelia Pharma AB (publ) (-3.91), greater than Biovica International AB (publ) (-0.60), greater than Sprint Bioscience AB (publ) (-6.07),
| Company | PE Ratio | Market cap |
|---|---|---|
| 6.79 | $949.70M | |
| 28.18 | $28.17B | |
| -3.91 | $347.27M | |
| -0.60 | $105.76M | |
| -6.07 | $155.64M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Asarina Pharma AB (publ) using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Asarina Pharma AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Asarina Pharma AB (publ)'s PE Ratio?
How is the PE Ratio calculated for Asarina Pharma AB (publ) (ASAP.ST)?
What is the highest PE Ratio for Asarina Pharma AB (publ) (ASAP.ST)?
What is the 3-year average PE Ratio for Asarina Pharma AB (publ) (ASAP.ST)?
What is the 5-year average PE Ratio for Asarina Pharma AB (publ) (ASAP.ST)?
How does the current PE Ratio for Asarina Pharma AB (publ) (ASAP.ST) compare to its historical average?